PlainRecalls
FDA Drug Low Class III Terminated

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

Reported: July 17, 2013 Initiated: March 15, 2013 #D-684-2013

Product Description

Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58

Reason for Recall

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

Details

Units Affected
36,708 blister packs
Distribution
Nationwide distribution. No foreign or government accounts.
Location
Sellersville, PA

Frequently Asked Questions

What product was recalled?
Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58. Recalled by Teva Pharmaceuticals USA, Inc.. Units affected: 36,708 blister packs.
Why was this product recalled?
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Which agency issued this recall?
This recall was issued by the FDA Drug on July 17, 2013. Severity: Low. Recall number: D-684-2013.